Prudential Financial Inc. Has $464,000 Stake in Xencor, Inc. (XNCR)

Prudential Financial Inc. decreased its position in Xencor, Inc. (NASDAQ:XNCR) by 12.4% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 21,994 shares of the biopharmaceutical company’s stock after selling 3,110 shares during the quarter. Prudential Financial Inc.’s holdings in Xencor were worth $464,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of XNCR. Bank of New York Mellon Corp grew its holdings in shares of Xencor by 15.8% in the 1st quarter. Bank of New York Mellon Corp now owns 198,988 shares of the biopharmaceutical company’s stock worth $4,759,000 after purchasing an additional 27,109 shares during the last quarter. Parametric Portfolio Associates LLC grew its holdings in shares of Xencor by 0.6% in the 1st quarter. Parametric Portfolio Associates LLC now owns 36,253 shares of the biopharmaceutical company’s stock worth $867,000 after purchasing an additional 209 shares during the last quarter. Victory Capital Management Inc. grew its holdings in shares of Xencor by 2,826.5% in the 1st quarter. Victory Capital Management Inc. now owns 28,533 shares of the biopharmaceutical company’s stock worth $682,000 after purchasing an additional 27,558 shares during the last quarter. American International Group Inc. grew its holdings in shares of Xencor by 18.0% in the 1st quarter. American International Group Inc. now owns 21,824 shares of the biopharmaceutical company’s stock worth $522,000 after purchasing an additional 3,332 shares during the last quarter. Finally, Teachers Advisors LLC grew its holdings in shares of Xencor by 1.2% in the 1st quarter. Teachers Advisors LLC now owns 323,782 shares of the biopharmaceutical company’s stock worth $7,745,000 after purchasing an additional 3,868 shares during the last quarter. 76.92% of the stock is currently owned by institutional investors and hedge funds.

XNCR has been the topic of several analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $29.00 target price on shares of Xencor in a report on Friday, June 16th. Canaccord Genuity reissued a “buy” rating and set a $36.00 price objective on shares of Xencor in a report on Tuesday, August 8th. Zacks Investment Research lowered shares of Xencor from a “hold” rating to a “sell” rating in a report on Friday, August 11th. BidaskClub lowered shares of Xencor from a “hold” rating to a “sell” rating in a report on Monday, August 14th. Finally, ValuEngine raised shares of Xencor from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Two analysts have rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $28.00.

In other Xencor news, major shareholder John S. Stafford III bought 41,016 shares of the firm’s stock in a transaction on Tuesday, August 22nd. The shares were purchased at an average price of $19.69 per share, for a total transaction of $807,605.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder John S. Stafford III bought 27,000 shares of the firm’s stock in a transaction on Friday, August 11th. The stock was acquired at an average price of $21.13 per share, for a total transaction of $570,510.00. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 215,551 shares of company stock worth $4,386,916. Company insiders own 4.14% of the company’s stock.

Shares of Xencor, Inc. (NASDAQ:XNCR) opened at 24.00 on Wednesday. The firm’s 50-day moving average is $22.27 and its 200-day moving average is $22.45. The company’s market cap is $1.13 billion. Xencor, Inc. has a one year low of $18.45 and a one year high of $29.38.

Xencor (NASDAQ:XNCR) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.10. Xencor had a negative return on equity of 13.79% and a negative net margin of 121.04%. The firm had revenue of $13.34 million for the quarter, compared to analysts’ expectations of $8.15 million. Analysts expect that Xencor, Inc. will post ($1.17) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/10/11/prudential-financial-inc-has-464000-stake-in-xencor-inc-xncr.html.

Xencor Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor, Inc. (NASDAQ:XNCR).

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply